Clinical Research Directory

Inclusion Criteria: Stage 1: 1. Age 18-years-old or older 2. Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included. 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed. 4. Able to understand study procedures and to comply with them for the entire length of the study. 5. Able to understand a written information sheet and willing to verbally consent. 6. Fluent in English (reading, writing, and speaking) Stage 2: 1. Age 18-years-old or older 2. Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included. 3. Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed. 4. Able to understand study procedures and to comply with them for the entire length of the study. 5. Fluent in English (reading, writing, and speaking). 6. Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following: 1. Somatic DNA testing of already-collected tissue. 2. Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure. 3. Blood-based DNA testing to evaluate for circulating tumor DNA. 7. Able to understand a written informed consent document and willing to sign it. Exclusion Criteria: Contraindication to any study-related procedure or assessment in either stage.